18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot.

Triumbari EKA, Lorusso M, Cirillo F, D'Orso F, Lolli V, De Rosa A, Di Carmine R, Meduri GM

Clinical nuclear medicine3 Feb 2026

PMID41650160DOI10.1097/rlu.0000000000006360PepBankPUB-41650160

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanCase report or seriesSafety outcome
In a woman with metastatic breast cancer, FDG PET/CT showed abnormal gastric retention suggestive of semaglutide-induced gastroparesis five days after the first dose.
In plain wordsIn one woman, a scan after the first semaglutide dose showed stomach emptying problems that fit semaglutide-induced gastroparesis.
Peptide
Semaglutide
Outcome
IncreaseGastroparesis on FDG PET/CT
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · single doseAs given in this study (human).
Source sentences
Summary
Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment.
Report a problemFND-4165016001
02HumanCase report or seriesSafety outcome
In a woman with metastatic breast cancer, FDG PET/CT showed gallbladder uptake suggestive of semaglutide-induced cholecystitis after the first dose.
In plain wordsIn one woman, a scan after the first semaglutide dose showed gallbladder changes that fit gallbladder inflammation.
Peptide
Semaglutide
Outcome
IncreaseCholecystitis on FDG PET/CT
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · single doseAs given in this study (human).
Source sentences
Summary
Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment.
Report a problemFND-4165016002
03HumanCase report or seriesSafety outcome
In a woman with metastatic breast cancer, FDG PET/CT showed colonic uptake suggestive of semaglutide-induced colitis after the first dose.
In plain wordsIn one woman, a scan after the first semaglutide dose showed bowel changes that fit colon inflammation.
Peptide
Semaglutide
Outcome
IncreaseColitis on FDG PET/CT
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · single doseAs given in this study (human).
Source sentences
Summary
Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment.
Report a problemFND-4165016003
04HumanCase report or seriesSafety outcome
In a woman with metastatic breast cancer, FDG PET/CT showed renal uptake suggestive of possible acute kidney injury secondary to dehydration after the first semaglutide dose.
In plain wordsIn one woman, a scan after the first semaglutide dose showed kidney changes that fit possible kidney injury from dehydration.
Peptide
Semaglutide
Outcome
IncreasePossible acute kidney injury on FDG PET/CT
Study
n = 1
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated · single doseAs given in this study (human).
Source sentences
Summary
Beyond oncologic findings, the scan revealed abnormal gastric retention, gallbladder, colonic, and renal uptake patterns suggestive of Semaglutide-induced gastroparesis, cholecystitis, colitis, and possible acute kidney injury secondary to dehydration.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment.
Report a problemFND-4165016004
05HumanCase report or seriesSafety outcome
In this patient, symptoms resolved after supportive therapy and withholding of semaglutide.
In plain wordsIn this one woman, symptoms went away after supportive care and stopping semaglutide.
Peptide
Semaglutide
Outcome
DecreaseRecovery after withholding semaglutide
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · single doseAs given in this study (human).
Source sentences
Summary
Symptoms resolved after supportive therapy and withholding of semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
We present the case of a 60-year-old woman with metastatic breast cancer who underwent 18 F-FDG PET/CT for treatment response assessment.
Report a problemFND-4165016005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.